Navigation Links
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
Date:11/1/2008

doses 12 hours apart, the concentration of ANA598 in plasma 12 hours after the second dose was 83 ug/mL, which substantially exceeds the level predicted to display antiviral potency. The data will be presented in a late-breaker poster titled "Results of a Phase I Safety, Tolerability and Pharmacokinetic Study of ANA598, a Non-Nucleoside NS5B Polymerase Inhibitor, in Healthy Volunteers", at 1:00 p.m. PST on Monday, November 3.

ANA598 Preclinical Data at AASLD Meeting

In addition to the results of the Phase I healthy volunteer study, Anadys is presenting additional data on the preclinical profile of ANA598 at the AASLD Meeting on Tuesday, November 4.

-- In a poster titled "In Vitro Studies Demonstrate that Combinations of Antiviral Agents that Include HCV Polymerase Inhibitor ANA598 have the Potential to Overcome Viral Resistance", Anadys will present the results of in vitro studies that show ANA598 to be synergistic with interferon-alpha, the protease inhibitor telaprevir (VX-950), and the nucleoside polymerase inhibitor PSI-6130 (the active agent of R7128). These studies also show that ANA598 retains activity against mutants known to confer resistance to other classes of direct antivirals, including protease inhibitors, nucleoside inhibitors and non-nucleosides that bind at the thumb site. Genotypic mutations resistant to ANA598 will be shown to be fully susceptible to interferon-alpha, telaprevir (VX-950) and PSI-6130. Data will also be presented demonstrating synergy between ANA598 and cytokines induced by ANA773, Anadys' TLR7 agonist oral prodrug, also in development for hepatitis C. These data strongly support the potential for ANA598 to be used in combination with multiple other agents approved or under investigation for hepatitis C.

-- In a poster titled "Antiviral Efficacy of the HCV RNA Polymerase Inhibitor ANA598 in the Chimpanzee Model of HCV Infection", Anadys will present data showing that ANA598 exhibits a substantial antivir
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
2. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
3. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
11. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... INDIANAPOLIS, Dec. 14 The ... RELPREVV (olanzapine) For Extended Release Injectable Suspension for ... and Company (NYSE: LLY ) announced ... the delivery of olanzapine for up to four ... short-acting formulations, long-acting formulations of antipsychotics allow for ...
(Date:12/14/2009)... Pf enex Inc. announced today that it ... an exclusive worldwide license to Pf enex Expression ... the production of specific proteins to be ... ,, Under the terms of the agreement ... in upfront and milestone payments as well as additional ...
(Date:12/14/2009)... SCRANTON, Pa., Dec. 14 CPG ... highly engineered building products, introduces VYCOM, a ... of the previous VYCOM Corporation and Scranton ... a wholly recognized business unit within CPG ... Scranton Products Commercial. The VYCOM business unit ...
Breaking Medicine Technology:FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 2FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 3FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 4FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 5FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 6FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 7FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 8Cardiogenesis Corporation Names Paul J McCormick Executive Chairman 49968 1Cardiogenesis Corporation Names Paul J McCormick Executive Chairman 49968 2Cardiogenesis Corporation Names Paul J McCormick Executive Chairman 49968 3Remarks As Prepared for Delivery by Attorney General Eric Holder at the Heat Press Conference on Detroit Takedown 49965 1Remarks As Prepared for Delivery by Attorney General Eric Holder at the Heat Press Conference on Detroit Takedown 49965 2Remarks As Prepared for Delivery by Attorney General Eric Holder at the Heat Press Conference on Detroit Takedown 49965 3AEterna Zentaris Receives US 2410 Million from Institutional Investors 12773 1AEterna Zentaris Receives US 2410 Million from Institutional Investors 12773 2AEterna Zentaris Receives US 2410 Million from Institutional Investors 12773 3
... WESTMINSTER, Colo., Dec. 27 Allos,Therapeutics, Inc. (Nasdaq: ... Data,Monitoring Committee (DMC) has completed the pre-specified 65-patient,safety ... 2 PROPEL trial of,PDX (pralatrexate) in patients with ... recommended that the trial continue per the,protocol. This ...
... Traditional Approval -, YARDLEY, Pa., Dec. 21 ... Supplemental New Drug Application (sNDA) to the U.S. ... (PI) PREZISTA(TM),(darunavir) tablets, which seeks traditional approval and ... adults. The application includes 48-week data from two,Phase ...
Other Medicine Technology:Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 2Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 3Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 4Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 5Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration 2Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration 3Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration 4Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration 5
(Date:12/14/2009)... and HOLLYWOOD, Fla., Dec. 14 ... today a definitive agreement to acquire STARLIMS ... leading provider of laboratory information management systems, ... ,, The acquisition strengthens Abbott,s competitive position ... web-based applications to help laboratories efficiently store, ...
(Date:12/14/2009)... -- The National Organization for Rare Disorders (NORD) today ... lifetime and annual health insurance caps. In a ... distributed widely on Capitol Hill, NORD said the current ... caps to continue for most Americans, contrary to what ... reform and welcomes the promises made by President Obama ...
(Date:12/14/2009)... government controlled health care, before moving to the U.S. to practice ... his new book, Health Reform: The End of the American Revolution?, ... its threat to real health care! , ... (PRWEB) ... from Minnesota, warns Americans not to sell out their liberty for ...
(Date:12/14/2009)... of Tens of Thousands of New Chronic Hepatitis ... -- Legislation approved by Congress providing for federal ... helping to reduce tens of thousands of new ... United States, the National Viral Hepatitis Roundtable ... included in the FY 2010 Consolidated Appropriations bill ...
(Date:12/14/2009)... Exercise benefited men whose disease had been treated, hadn,t ... -- Exercise appears to reduce the risk of death ... study, which began in January 1986, included 668 men ... stage III colon cancer that had not spread (nonmetastatic ... that asked them about any new cancer and disease ...
Breaking Medicine News(10 mins):Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 2Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 3Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 4Health News:NORD Calls for Immediate End to Lifetime Insurance Caps 2Health News:Canadian Doctor Warns Against Government-Run, Socialized Medicine and its Threat to Health Care and Freedom in America 2Health News:NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange 2Health News:Physical Activity May Prolong Survival After Colon Cancer 2
... India's leading vaccine manufacturer Serum Institute of India has manufactured ... vaccines // . ,The vaccine is called Td-Vac ... adolescents and adults. The new vaccine will replace the existing ... ,Td-Vac is priced at Rs 7.50 whereas the TT ...
... health the status of industry. The positive step forward ... provided under the industrial policy. Nursing homes // and ... ,The government move is expected to give a ... state, where half the population lives below the poverty ...
... a test that can detect the Hepatitis C virus using ... of Soroka University Medical Centre // in Israel carried ... functions whose blood must be passed through a machine to ... ,Such patients have a high incidence of Hepatitis C. ...
... give a false picture about coma survival and recovery rates ... felt // by coma patients and found that the ... not true as the study show that only 8% of ... with 50% upwards in real life. ,The recovery ...
... Health experts in the United States fear that if the deadly ... risk since they are vulnerable // to the H5N1 virus. ... 70 lives in Asia and has appeared in parts of Europe ... slaughtered in an effort to contain the virus. However, experts fear ...
... University of Pennsylvania have obtained valuable insights into various ... // called functional magnetic resonance imaging. It has been ... are active during an event are re-activated when a ... study shows that, as you search for memories of ...
Other Medicine News:Health News:Magnetic Resonance Imaging Can Now Be Used For Mind Reading 2
The MULTI-LINK RX PENTA Coronary Stent Systems with new ACCESS-LINK Stent Design are indicated for improving coronary luminal diameter....
Take Performance to a Higher Level....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
FemoStop plus system is a femoral compression system for hemostasis management. It provides a comfortable and efficient "hands off method of compressing the femoral artery and vein after diagnostic ...
Medicine Products: